(PSYCHIATRIC TIMES) - Panic disorder (PD) is a common psychiatric illness that can have a chronic, relapsing course. Epidemiological data has documented a lifetime prevalence of 0.4% to 3.5%, and the illness usually begins during early to middle adulthood with a female to male preponderance (Weissman et al., 1997). Other data have shown that after remission of panic symptoms, women may be more likely than men to experience recurrence of panic attacks (Yonkers et al., 1998).
The question of whether pregnancy represents a time of increased risk for recurrence of panic symptoms has been a matter of debate. Several authors have suggested that pregnancy may provide a protective effect in the course of panic disorder. For example, George et al. (1987) reported a small case series of three women with PD who showed marked improvement in their panic symptoms during pregnancy. Villeponteaux et al. (1992) conducted a small retrospective study on pregnant women with pre-existing PD and reported that a majority of women had an improvement in panic symptoms during pregnancy. Altshuler et al. (1998) found that whereas pregnancy appears to exacerbate symptoms of obsessive compulsive disorder, patients with PD may remain well during pregnancy even after discontinuing medication. In contrast to the above findings, Cohen et al. (1996) conducted a small prospective study on the course of pre-existing PD during pregnancy and found that most patients continued to experience panic attacks during all three trimesters and required anti-panic medication.
Our group has conducted a seven-year, naturalistic follow-up study in order to examine the effect of pregnancy on the course of pre-existing panic disorder. Our results demonstrated that pregnancy may confer an increased risk of relapse in PD. Moreover, when compared to patients who develop PD while not pregnant, patients who have the initial onset of PD during pregnancy appear to have a higher risk of relapse at the time of a subsequent pregnancy (Dannon, unpublished data).
While the effect of pregnancy seems to have a variable influence on the course of PD, multiple studies have demonstrated that the postpartum period appears to be associated with an increased risk of relapse (Cohen et al., 1996; Northcott and Stein, 1994; Sholomskas et al., 1993; Wenzel et al., 2005). It should be noted that Wisner et al. (1996) conducted a historical, prospective study of women with panic disorder (n=22) and found no change in the course of panic symptoms postnatally, as compared to the pre-pregnancy baseline. On the other hand, one interesting observation from this study was that first lifetime onset of PD was common postpartum.
While it is well accepted that PD has disabling effects in terms of social and occupational functioning, there is also evidence that untreated anxiety in pregnant women may adversely affect the developing fetus. In a cohort of 100 pregnant women with a mean gestation of 32 weeks, Teixeira et al. (1999) found a significant association between uterine artery resistance and maternal scores for state and trait anxiety. Another finding was the strong correlation between plasma levels in the mother and in the fetus, leading the investigators to postulate that elevated maternal cortisol may have a direct effect on the development of the fetal brain (Glover, 1999). In support of this theory, it has been suggested that the hypothalamic-pituitary-adrenocortical (HPA) system (elevated cortisol levels) or sympathetic activation may have contributed to the findings of increased uterine artery resistance in anxious mothers (Field et al., 2003).
The approach to treating the pregnant woman with symptomatic PD must take into consideration the potential risks to the fetus of pharmacotherapeutic intervention versus the possible risks of untreated maternal anxiety. Benzodiazepines are widely prescribed for the treatment of panic disorder, but their use should generally be avoided in women who are pregnant or who wish to conceive.
For full article, please visit: